SCHEMBL3672965

SCHEMBL3672965

CCC(C)CC(=O)N1CCN(c2ccc(C(=O)NC(C)CCc3ccccc3)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
SMN1; SMN2 Q16637 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
HTT P42858 2/20 0.51
HPGD P15428 2/20 0.48
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
TSHR P16473 1/20 0.48
ME2 P23368 2/20 0.48
ME1 P48163 2/20 0.48
ME3 Q16798 2/20 0.48
HSP90AA1 P07900 1/20 0.47
SCD O00767 2/20 0.46
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668366 0.89 SCD (0.43) LMNASMN1; SMN2HPGDALDH1A1NPC1
SCHEMBL3677309 0.88 LMNA (0.55) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3678722 0.87 RAB9A (0.64) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3677187 0.86 LMNA (0.55) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3673395 0.85 SCD (0.43) SMN1; SMN2KMT2AHPGDALDH1A1NPC1
SCHEMBL3673627 0.85 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTHPGDMAPT
SCHEMBL3669021 0.85 SMN1; SMN2 (0.55) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3673912 0.85 LMNA (0.54) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3672230 0.84 ALDH1A1 (0.54) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL3677228 0.83 LMNA (0.52) LMNASMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT LMNA 175/4885SMN1; SMN2 112/4885KMT2A 3998/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 LMNA 369/4885SMN1; SMN2 123/4885KMT2A 3153/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT LMNA 175/4885SMN1; SMN2 112/4885KMT2A 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.